Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells $217,413.00 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 63,945 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $3.40, for a total value of $217,413.00. Following the transaction, the chief executive officer owned 533,122 shares in the company, valued at approximately $1,812,614.80. This represents a 10.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total value of $322,718.41.
• On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.51, for a total value of $359,406.45.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.48, for a total value of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total value of $16,881.00.

Whitehawk Therapeutics Trading Down 0.6%

Shares of WHWK stock traded down $0.02 during midday trading on Wednesday, reaching $3.41. 212,634 shares of the stock were exchanged, compared to its average volume of 201,638. Whitehawk Therapeutics, Inc. has a 1 year low of $1.39 and a 1 year high of $4.48. The company’s 50 day moving average is $3.32 and its two-hundred day moving average is $2.69. The firm has a market cap of $160.95 million, a PE ratio of 7.26 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21.

Institutional Trading of Whitehawk Therapeutics

Hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $5,414,000. Suvretta Capital Management LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $7,030,000. Ally Bridge Group NY LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $1,554,000. Peapod Lane Capital LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $577,000. Finally, ABG Innovation Capital Partners III GP Ltd bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $51,000. 52.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. JonesTrading assumed coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Wall Street Zen upgraded Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, Oppenheimer initiated coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.50.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.